AI assistant
Marker Therapeutics, Inc. — Director's Dealing 2018
Oct 18, 2018
35150_dirs_2018-10-18_84bb4717-5a1f-4359-a187-37c115469bcd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Marker Therapeutics, Inc. (MRKR)
CIK: 0001094038
Period of Report: 2018-10-17
Reporting Person: Sonsini Peter W. (10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 5000000 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrant to Purchase Common Stock (right to buy) | $5.00 | 2023-10-17 | Common Stock (3750000) | Indirect |
Footnotes
F1: The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest.